Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Long-Term Debt Repayments (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Long-Term Debt Repayments data on record, last reported at $104000.0 in Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments fell 9.57% year-over-year to $104000.0; the TTM value through Dec 2025 reached $223000.0, down 97.3%, while the annual FY2025 figure was $223000.0, 97.3% down from the prior year.
  • Long-Term Debt Repayments reached $104000.0 in Q4 2025 per AMPH's latest filing, up from $44000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $200.1 million in Q3 2023 and bottomed at $37000.0 in Q2 2025.
  • Average Long-Term Debt Repayments over 5 years is $18.3 million, with a median of $565500.0 recorded in 2022.
  • Peak YoY movement for Long-Term Debt Repayments: skyrocketed 39081.25% in 2023, then tumbled 99.98% in 2024.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $613000.0 in 2021, then plummeted by 79.12% to $128000.0 in 2022, then surged by 39081.25% to $50.2 million in 2023, then plummeted by 99.77% to $115000.0 in 2024, then decreased by 9.57% to $104000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were $104000.0 in Q4 2025, $44000.0 in Q3 2025, and $37000.0 in Q2 2025.